× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En Fr

Our approach

adjuvant therapies

anticoagulant 2

anticoagulant, curative dose 5

anticoagulant, pre-admission 3

anticoagulant, prophylactic dose 4

anticoagulation, intermediate prophylactic dose 1

heparin at therapeutic dose

hydrogen-oxygen nebulizer

hyperbaric oxygen

pulmonary rehabilitation

anti-inflammatoty and immuno-therapy

acalabrutinib 2

anti-inflammatory therapies 1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs 8

sodium aescinate

corticosteroids 7

dexamethasone 5

Dexamethasone 12mg 1

Hydrocortisone 4

low-dose corticosteroids

methylprednisolone 6

Immunostimulants drugs

anti-PD-1 antibody

convalescent plasma treatment 28

Early convalescent plasma. 1

immunoglobulin therapy 4

inactivated mycobacterium vaccine

high-dose IFN beta-1a 1

inhaled interferon

recombinant super-compound interferon rSIFN-co 1

SNG001 inhaled interferon beta 1

interferon / TFF2 1

peginterferon 3

neutralizing antibody

bamlanivimab monotherapy 2

bamlanivimab plus etesevimab 3

BRII-196 and BRII-198 (Brii Biosciences)

casirivimab and imdevimab (REGN-COV2) 2

equine polyclonal antibodies INM005 1

regdanvimab (CT-P59 Celltrion) 1

sotrovimab (VIR-7831) 2

Immunosuppressants drugs

anti-interleukin-6

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

complement inhibitors

janus kinase (JAK) inhibitor

inhaled corticosteroids

Polyinosinic-Polycytidylic Acid

5-alpha-reductase inhibitors

proxalutamide 3

antiviral and associated therapy

ASC09/ritonavir

azithromycin 10

azithromycin plus hydroxychloroquine 3

baloxavir marboxil 1

chloroquine and derivatives 1

hydroxychloroquine 44

danoprevir / ritonavir

darunavir cobicistat 1

darunavir/cobicistat plus chloroquine

favipiravir plus interferon 1

hydroxychloroquine plus macrolides 8

ivermectin plus doxycycline 3

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 9

lopinavir/ritonavir plus interferon ß-1a 1

lopinavir/ritonavir, ribavirin and interferon beta-1b 1

oseltamivir plus chloroquin

Renin-angiotensin-system-acting agents 7

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs) 3

angiotensin-(1-7)

discontinuation of ACEI/ARB 3

RAS blocker withdrawal

sofosbuvir and daclatasvir 5

sofosbuvir and ledipasvir 2

tenofovir/emtricitabine 1

tranexamic acid

umifenovir (arbidol) 5

clarithromycine 2

prone positioning

2-deoxy-D-glucose (2-DG)

alpha lipoic acid 1

BLD-2660 (calpain inhibitor)

calcium channel blocker

camostat mesilate 1

continuous positive airway pressure (CPAP)

cytokine adsorption

dapagliflozin 1

diammonium glycyrrhizinate

DPP-4 inhibitor

kinin-kallikrein inhibitors

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

povidone-iodine 1

proton pump inhibitors (PPI) 6

PUL-042 inhalation solution

zinc plus vitamin c 1

respiratory support

BCG vaccination

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy -